Cargando…

Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye

Renal medullary carcinoma (RMC) is a lethal disease that predominantly afflicts young individuals with sickle cell trait. Our recently reported molecular profiling of primary untreated RMC tissues elucidated distinct genomic and immune hallmarks of RMC, and identified MYC-induced replication stress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Msaouel, Pavlos, Walker, Cheryl L., Genovese, Giannicola, Tannir, Nizar M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Author's Views
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469578/ https://www.ncbi.nlm.nih.gov/pubmed/32944636 http://dx.doi.org/10.1080/23723556.2020.1777060

Ejemplares similares

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2
por: Sarkar, Sanila, et al.
Publicado: (2023)

Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy
por: Shapiro, Daniel D., et al.
Publicado: (2023)

Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression
por: Di Carlo, Emma
Publicado: (2014)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

The PVT1-MYC duet in cancer
por: Tseng, Yuen-Yi, et al.
Publicado: (2015)

Targeting MYC through WDR5
por: Thomas, Lance R., et al.
Publicado: (2020)

Cytoplasmic MYC is an anti-necroptotic protein
por: Lee, Eun-Woo, et al.
Publicado: (2020)

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
por: Linch, Stefanie N, et al.
Publicado: (2014)

Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?
por: Msaouel, Pavlos, et al.
Publicado: (2019)

Role of c-MYC in tumor-associated macrophages and cancer progression
por: Pello, Oscar M., et al.
Publicado: (2013)

Do changes in the c-MYC coding sequence contribute to tumorigenesis?
por: Chakraborty, Abhishek A., et al.
Publicado: (2014)

The pan-cancer lncRNA MILIP links c-Myc to p53 repression
por: Feng, Yu Chen, et al.
Publicado: (2020)

CTLs regulate tumor growth via cytostatic effects rather than cytotoxicity: a few T cells can influence the growth of many times more tumor cells
por: Kakimi, Kazuhiro, et al.
Publicado: (2014)

ADHFE1 is a MYC-linked oncogene that induces metabolic reprogramming and cellular de-differentiation in breast cancer
por: Mishra, Prachi, et al.
Publicado: (2018)

WNT-mediated gene gating: a novel principle connecting oncogenic super-enhancers with the nuclear pore to drive pathological expression of MYC
por: Göndör, Anita
Publicado: (2020)

More than meets the dimer: What is the quaternary structure of the glucocorticoid receptor?
por: Presman, Diego M., et al.
Publicado: (2016)

Telomeres and sirtuins: at the end we meet again
por: Amano, Hisayuki, et al.
Publicado: (2019)

SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance
por: Vokshi, Bujamin H., et al.
Publicado: (2023)

Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies
por: Shapiro, Daniel D., et al.
Publicado: (2021)

Endosome traffic machinery meets the p53–p21 axis
por: Barroso-González, Jonathan, et al.
Publicado: (2014)

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma
por: Msaouel, Pavlos, et al.
Publicado: (2017)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
por: Gujar, Shashi A, et al.
Publicado: (2014)

More to physics than meets the eye
Publicado: (2002)

More to physics than meets the eye
por: Fraser, Gordon Murray
Publicado: (2002)

More to Mutton than Meets the Eye
por: Pierce, Read G., et al.
Publicado: (2010)

More to voxelotor than meets the eye?
por: Bovino, Robert C., et al.
Publicado: (2022)

Under one roof: The bone marrow survival niche for multiple myeloma and normal plasma cells
por: Nair, Jayakumar R., et al.
Publicado: (2012)

More than two decades trapped
por: Qiu, Cheng-Wei, et al.
Publicado: (2018)

Getting by with a little help from the right CD4(+) T cells
por: Hoepner, Sabine, et al.
Publicado: (2013)

Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment
por: Schuessler, Andrea, et al.
Publicado: (2014)

Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis
por: Esagian, Stepan M., et al.
Publicado: (2021)

Cell-penetrating peptides—the Swiss Army knife of cancer vaccines
por: Walker, Paul R., et al.
Publicado: (2015)

Development of interferon γ-based immunocytokines targeting renal cancer
por: Chen, Peirong, et al.
Publicado: (2013)

Dysregulation of HIF2α and autophagy in renal cell carcinoma
por: Liu, Xian-De, et al.
Publicado: (2014)

Is there more to glycaemic control than meets the eye?
por: Chase, J Geoffrey, et al.
Publicado: (2007)

There is more to A.C.S. than meets the eye
por: Bhattacharya, Surajit
Publicado: (2014)

The Postsynaptic Density: There Is More than Meets the Eye
por: Dosemeci, Ayse, et al.
Publicado: (2016)

Survival analysis, more than meets the eye
por: Lucijanic, Marko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0qkq8q7t2j70rh41e9db201uld